Extensive Labeling Required Under Device Remarketers' Voluntary System
This article was originally published in The Gray Sheet
Executive Summary
Device remarketers and servicers should indicate whether reserviced devices are "ready for clinical use" or "must be checked for proper performance and safety" under a proposed voluntary registration system issued Sept. 9 by an industry task force coordinated by the Association for the Advancement of Medical Instrumentation.
You may also be interested in...
FDA To Issue Remarketer Labeling Regs, Monitor Registration System
Device remarketers that label serviced devices as "ready for clinical use" under a recently proposed voluntary registration system will be subject to FDA enforcement action if the devices do not meet performance specifications, according to FDA staffers.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.